医学
2019年冠状病毒病(COVID-19)
大流行
重症监护医学
疾病
梅德林
临床试验
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
随机对照试验
2019-20冠状病毒爆发
内科学
传染病(医学专业)
爆发
病毒学
政治学
法学
作者
Grace Chung‐Yan Lui,Giovanni Guaraldi
出处
期刊:Current Opinion in Pulmonary Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2023-03-14
卷期号:29 (3): 174-183
被引量:14
标识
DOI:10.1097/mcp.0000000000000953
摘要
COVID-19 pandemic has caused more than 6.6 million deaths globally. Tremendous efforts have been committed for the development of new and repurposed drugs for the treatment of COVID-19. Although different international and national guidelines share consensus in the management of COVID-19 disease with different levels of severity, new challenges have emerged, steering the need for ongoing research in advancing the clinical management of COVID-19.This review focuses on recent data from randomized trials and postmarketing real-world evidence for the treatment of mild to moderate disease in the outpatient setting and patients hospitalized for COVID-19 with varying level of severity. Relevant data for treatment of the latest omicron sub-variants in people who received vaccination are presented. Challenges in special populations, including immunocompromised hosts, patients with renal failure and pregnant women, are also discussed.Treatment of COVID-19 should be personalized according to host characteristics, degree of severity and available treatment options.
科研通智能强力驱动
Strongly Powered by AbleSci AI